CXCR4 expression is often up-regulated in haematological malignancies15, and correlates with therapy resistance and poor prognosis in acute myelogenous leukaemia (AML) and non-Hodgkin lymphoma (NHL)16–19. This evidence concerns the gene CXCR4 and non-Hodgkin lymphoma.